Amanta Healthcare Q1FY27 Revenue ₹68.8 Cr, PAT ₹3.3 Cr
Amanta Healthcare Limited announced its unaudited financial results for the quarter ended June 30, 2026. Revenue for Q1FY27 stood at ₹68.8 crore, a 5.4% year-on-year growth, attributed to an improved product mix and better price realizations. EBITDA was ₹15.2 crore, with margins at 22%, a decrease from 24% in Q1FY26 due to increased raw material, employee, and operating costs. Profit After Tax (PAT) declined by 5.6% YoY to ₹3.3 crore, impacted by higher finance costs from a new Solar Term Loan. The company is progressing with capacity expansion, expecting the Steriport plant to be commissioned by Q2FY27 and SVP expansion by Q4FY27, alongside a solar power project to enhance manufacturing capacity and cost efficiency.
Key Highlights
- Q1FY27 revenue grew 5.4% YoY to ₹68.8 crore.
- EBITDA margins moderated to 22% from 24% due to cost increases.
- PAT decreased 5.6% YoY to ₹3.3 crore, impacted by higher finance costs.
- Capacity expansion projects (Steriport, SVP) are on track for FY27 commissioning.
- A captive solar power project aims to improve cost efficiencies.
Price Impact
More from AMANTA